Physician profile
Matthew Cary
NPI 1619233525
$15,084.58
in general payments reported to CMS, 2019-2025
29 companies · $3,549 in 2025
The $3,549 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $1,153 · 2023: $2,197 · 2024: $7,865 · 2025: $3,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,308 · Consulting Fee: $3,680 · Travel and Lodging: $2,297 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,308.24 |
| Consulting Fee | $3,680.00 |
| Travel and Lodging | $2,297.29 |
| Education | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,927.86 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $3,476.07 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Theratechnologies INC. | $712.55 | 2021-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Lilly USA, LLC | $588.83 | 2023-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $567.22 | 2021-2025 | Pifeltro, Delstrigo, Isentress |
| Janssen Biotech, INC. | $566.59 | 2021-2023 | Symtuza |
| Napo Pharmaceuticals INC | $377.18 | 2021-2025 | Mytesi |
| Novo Nordisk INC | $300.86 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $247.28 | 2023-2025 | Repatha, Otezla, Repatha |
| Emd Serono, INC. | $215.20 | 2023 | Serostim |
| Astrazeneca Pharmaceuticals LP | $201.03 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $194.63 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.66 | 2021-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $78.95 | 2022-2024 | Keveyis |
| Halozyme INC | $64.49 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.29 | 2025 | |
| Antares Pharma, INC. | $48.86 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Hologic Sales and Service, LLC | $47.76 | 2024-2025 | Third Wave, Aptima, Thinprep 2000 Processor |
| Janssen Scientific Affairs, LLC | $44.18 | 2023 | Symtuza |
| Acerus Pharmaceuticals Corporation | $39.91 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.03 | 2024-2025 | Caplyta |
| Vbi Vaccine (Delaware) INC. | $38.57 | 2022 | |
| Exact Sciences Corporation | $33.76 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $30.71 | 2022 | |
| Pfizer INC. | $29.52 | 2023-2024 | |
| Mirum Pharmaceuticals, INC. | $20.42 | 2025 | Cholbam |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.03 | 2022 | |
| Insmed, INC. | $15.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.16 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.